INnoVative trial design for testing the Efficacy, Safety and Tolerability of 6‐month treatment with incretin‐based therapy to prevent type 1 DIAbetes in autoantibody positive participants: A protocol for three parallel double‐blind, randomised controlled trials (INVESTDIA)

AIMS: β‐cell stress and dysfunction may contribute to islet autoimmunity and progression to clinical type 1 diabetes. We present a protocol of three randomised controlled trials assessing the effects of glucagon‐like peptide 1 (GLP − 1) analogue liraglutide in three early stages of type 1 diabetes....

Descripción completa

Detalles Bibliográficos
Autores principales: Kero, Jukka, Koskenniemi, Jaakko J., Karsikas, Sara, Pokka, Tytti, Lou, Olivia, Toppari, Jorma, Veijola, Riitta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Study Protocols
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540026/
https://www.ncbi.nlm.nih.gov/pubmed/35797241
http://dx.doi.org/10.1111/dme.14913

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9540026/
https://www.ncbi.nlm.nih.gov/pubmed/35797241
http://dx.doi.org/10.1111/dme.14913

Ejemplares similares